Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells

Abhik Bandyopadhyay, Yong Zhu, Shazli N. Malik, Jeffrey Kreisberg, Michael G. Brattain, Eugene A. Sprague, Jian Luo, Fernando López-Casillas, L. Z. Sun

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

TGFβ overexpression in human cancer cells has been shown to promote tumor progression. In the present study, we sought to determine whether sequestration of endogenous TGFβ by the expression of a soluble TGFβ type III receptor (sRIII), can reduce malignancy in human carcinoma cells and whether the tumor-suppressive activity of sRIII is associated with the inhibition of angiogenesis. Ectopic expression of sRIII significantly inhibited the growth of tumors formed by human colon carcinoma HCT116 and breast carcinoma MDA-MB-435 cells in nude mice. It also reduced the metastatic potential of the MDA-MB-435 cells. Thus, endogenous TGFβ appears to be necessary for the progression of these two carcinomas. Furthermore, when the tumor cells were mixed with Matrigel and embedded subcutaneously in nude mice, the blood volume in Matrigel plugs containing sRIII-expressing cells as indicated by hemoglobin levels was significantly lower than that in Matrigel plugs containing the respective control cells. Blood vessel counts in paraffin sections of the Matrigel plugs containing sRIII-expressing cells were also significantly lower than those in paraffin sections of the Matrigel plugs containing control cells. Treatment of human endothelial cells with a recombinant sRIII significantly inhibited their ability to form a capillary web structure on Matrigel. These results for the first time indicate that the sRIII-induced tumor suppression appears to be in part due to the inhibition of angiogenesis.

Original languageEnglish (US)
Pages (from-to)3541-3551
Number of pages11
JournalOncogene
Volume21
Issue number22
DOIs
StatePublished - Jan 1 2002

Fingerprint

Growth
Neoplasms
Carcinoma
Nude Mice
Paraffin
Blood Volume
Blood Vessels
matrigel
Colon
Hemoglobins
Endothelial Cells
Breast Neoplasms

Keywords

  • Angiogenesis
  • Metastasis
  • TGFβ
  • Tumor growth
  • Type III receptor

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Bandyopadhyay, A., Zhu, Y., Malik, S. N., Kreisberg, J., Brattain, M. G., Sprague, E. A., ... Sun, L. Z. (2002). Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene, 21(22), 3541-3551. https://doi.org/10.1038/sj.onc.1205439

Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells. / Bandyopadhyay, Abhik; Zhu, Yong; Malik, Shazli N.; Kreisberg, Jeffrey; Brattain, Michael G.; Sprague, Eugene A.; Luo, Jian; López-Casillas, Fernando; Sun, L. Z.

In: Oncogene, Vol. 21, No. 22, 01.01.2002, p. 3541-3551.

Research output: Contribution to journalArticle

Bandyopadhyay, A, Zhu, Y, Malik, SN, Kreisberg, J, Brattain, MG, Sprague, EA, Luo, J, López-Casillas, F & Sun, LZ 2002, 'Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells', Oncogene, vol. 21, no. 22, pp. 3541-3551. https://doi.org/10.1038/sj.onc.1205439
Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA et al. Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene. 2002 Jan 1;21(22):3541-3551. https://doi.org/10.1038/sj.onc.1205439
Bandyopadhyay, Abhik ; Zhu, Yong ; Malik, Shazli N. ; Kreisberg, Jeffrey ; Brattain, Michael G. ; Sprague, Eugene A. ; Luo, Jian ; López-Casillas, Fernando ; Sun, L. Z. / Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells. In: Oncogene. 2002 ; Vol. 21, No. 22. pp. 3541-3551.
@article{2077229c17844d5ca57c44c3a5a6fb67,
title = "Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells",
abstract = "TGFβ overexpression in human cancer cells has been shown to promote tumor progression. In the present study, we sought to determine whether sequestration of endogenous TGFβ by the expression of a soluble TGFβ type III receptor (sRIII), can reduce malignancy in human carcinoma cells and whether the tumor-suppressive activity of sRIII is associated with the inhibition of angiogenesis. Ectopic expression of sRIII significantly inhibited the growth of tumors formed by human colon carcinoma HCT116 and breast carcinoma MDA-MB-435 cells in nude mice. It also reduced the metastatic potential of the MDA-MB-435 cells. Thus, endogenous TGFβ appears to be necessary for the progression of these two carcinomas. Furthermore, when the tumor cells were mixed with Matrigel and embedded subcutaneously in nude mice, the blood volume in Matrigel plugs containing sRIII-expressing cells as indicated by hemoglobin levels was significantly lower than that in Matrigel plugs containing the respective control cells. Blood vessel counts in paraffin sections of the Matrigel plugs containing sRIII-expressing cells were also significantly lower than those in paraffin sections of the Matrigel plugs containing control cells. Treatment of human endothelial cells with a recombinant sRIII significantly inhibited their ability to form a capillary web structure on Matrigel. These results for the first time indicate that the sRIII-induced tumor suppression appears to be in part due to the inhibition of angiogenesis.",
keywords = "Angiogenesis, Metastasis, TGFβ, Tumor growth, Type III receptor",
author = "Abhik Bandyopadhyay and Yong Zhu and Malik, {Shazli N.} and Jeffrey Kreisberg and Brattain, {Michael G.} and Sprague, {Eugene A.} and Jian Luo and Fernando L{\'o}pez-Casillas and Sun, {L. Z.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1038/sj.onc.1205439",
language = "English (US)",
volume = "21",
pages = "3541--3551",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "22",

}

TY - JOUR

T1 - Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells

AU - Bandyopadhyay, Abhik

AU - Zhu, Yong

AU - Malik, Shazli N.

AU - Kreisberg, Jeffrey

AU - Brattain, Michael G.

AU - Sprague, Eugene A.

AU - Luo, Jian

AU - López-Casillas, Fernando

AU - Sun, L. Z.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - TGFβ overexpression in human cancer cells has been shown to promote tumor progression. In the present study, we sought to determine whether sequestration of endogenous TGFβ by the expression of a soluble TGFβ type III receptor (sRIII), can reduce malignancy in human carcinoma cells and whether the tumor-suppressive activity of sRIII is associated with the inhibition of angiogenesis. Ectopic expression of sRIII significantly inhibited the growth of tumors formed by human colon carcinoma HCT116 and breast carcinoma MDA-MB-435 cells in nude mice. It also reduced the metastatic potential of the MDA-MB-435 cells. Thus, endogenous TGFβ appears to be necessary for the progression of these two carcinomas. Furthermore, when the tumor cells were mixed with Matrigel and embedded subcutaneously in nude mice, the blood volume in Matrigel plugs containing sRIII-expressing cells as indicated by hemoglobin levels was significantly lower than that in Matrigel plugs containing the respective control cells. Blood vessel counts in paraffin sections of the Matrigel plugs containing sRIII-expressing cells were also significantly lower than those in paraffin sections of the Matrigel plugs containing control cells. Treatment of human endothelial cells with a recombinant sRIII significantly inhibited their ability to form a capillary web structure on Matrigel. These results for the first time indicate that the sRIII-induced tumor suppression appears to be in part due to the inhibition of angiogenesis.

AB - TGFβ overexpression in human cancer cells has been shown to promote tumor progression. In the present study, we sought to determine whether sequestration of endogenous TGFβ by the expression of a soluble TGFβ type III receptor (sRIII), can reduce malignancy in human carcinoma cells and whether the tumor-suppressive activity of sRIII is associated with the inhibition of angiogenesis. Ectopic expression of sRIII significantly inhibited the growth of tumors formed by human colon carcinoma HCT116 and breast carcinoma MDA-MB-435 cells in nude mice. It also reduced the metastatic potential of the MDA-MB-435 cells. Thus, endogenous TGFβ appears to be necessary for the progression of these two carcinomas. Furthermore, when the tumor cells were mixed with Matrigel and embedded subcutaneously in nude mice, the blood volume in Matrigel plugs containing sRIII-expressing cells as indicated by hemoglobin levels was significantly lower than that in Matrigel plugs containing the respective control cells. Blood vessel counts in paraffin sections of the Matrigel plugs containing sRIII-expressing cells were also significantly lower than those in paraffin sections of the Matrigel plugs containing control cells. Treatment of human endothelial cells with a recombinant sRIII significantly inhibited their ability to form a capillary web structure on Matrigel. These results for the first time indicate that the sRIII-induced tumor suppression appears to be in part due to the inhibition of angiogenesis.

KW - Angiogenesis

KW - Metastasis

KW - TGFβ

KW - Tumor growth

KW - Type III receptor

UR - http://www.scopus.com/inward/record.url?scp=0037118579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037118579&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1205439

DO - 10.1038/sj.onc.1205439

M3 - Article

C2 - 12032856

AN - SCOPUS:0037118579

VL - 21

SP - 3541

EP - 3551

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 22

ER -